Product Highlight - Lonsurf
29 Mar 2019
- Active Ingredient: Trifluridine, tipiracil (as hydrochloride)
- Indications: Lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.
- Dosage & Administration: The recommended starting dose of Lonsurf in adults is 35 mg/m2/dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle as long as benefit is observed or until unacceptable toxicity occurs.
Lonsurf is for oral use. The tablets must be taken with a glass of water within 1 hour after completion of the morning and evening meals.
- Presentation: 15 mg/6.14 mg FC tab 2 x 10’s. 20 mg/8.19 mg FC tab 2 x 10’s.